Equitable Access and Regulatory News Archives

February 15, 2023

Disparities According to Genetic Ancestry in the Use of Precision Oncology Assays

While not specifically about chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), these results offer some encouraging news regarding cancer care for adults with predominantly African ancestry in terms of their use of genomic testing to help inform their cancer treatments.

January 30, 2023

FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

On 1/27/23 [email protected] announced the Federal Drug Administration (FDA)’s accelerated approval of pirtobrutinib in adult patients with relapsed or refractory mantle cell lymphoma (MCL) following at least 2 lines of systemic therapy, including a BTK inhibitor.

January 30, 2023

FDA Announces Evusheld is Not Currently Authorized for Emergency Use in the U.S.

As of 1/26/23, Evusheld (tixagevimab co-packaged with cilgavimab) is no longer available as Pre-Exposure Prophylaxis (PrEP) in the United States. That decision was made because as the virus continued to mutate, now over 90% of SARS-CoV-2 variants of concerns (VOC) circulating in the U.S. are no longer believed to

January 19, 2023

Zanubrutinib Approved in the U.S. for Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL)

With the FDA’s approval of zanubrutinib, CLL/SLL patients have another very strong choice to manage their disease.

December 6, 2022

MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting

Zandelisib joins umbralisib in the parade of PI3K inhibitors that won’t be developed as an option for chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) patients that have run out of options.

November 3, 2022

ASCO 2022: Survival Outcomes in Patients with Chronic Lymphocytic Leukemia Treated at Academic Centers

Chronic lymphocytic leukemia (CLL) patients treated at academic centers live lived longer than those treated at non-academic centers, but the data was confounded by significant demographic and socioeconomic variation between CLL patients treated at Academic Centers and Non-Academic Centers.

October 21, 2022

Some Good News About Costs for Targeted Oral Anti-Cancer Drugs for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Many chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients are insured under Medicare – either Original Medicare with a drug plan (Part A, B, and D “a la carte”) or a Medicare Advantage Plan (including Parts A, B, and D Prix fixe). Unfortunately, over the past several years, drug costs

October 19, 2022

ASCO 2022: Racial and Socioeconomic Disparities among Patients with Chronic Lymphocytic Leukemia: Analysis of Surveillance, Epidemiology, and End Results Program Data

The team at Ohio State University Comprehensive Cancer Center used Surveillance, Epidemiology, and End Results (SEER) data to determine how race and socioeconomic status (SES) affect survival for those with CLL. SEER is a free resource of the NIH, specifically the National Cancer Institute (NCI), and is “an authoritative

October 18, 2022

The Inflation Reduction Act: Big Changes to Medicare

CLL Society is proud to have been part of a coalition that led to changes that will result in lower out-of-pocket prescription drug costs for people on Medicare. What does this mean for people with CLL and SLL? Here are a few highlights:

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Equitable Access and Regulatory News

Disparities According to Genetic Ancestry in the Use of Precision Oncology Assays

FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

FDA Announces Evusheld is Not Currently Authorized for Emergency Use in the U.S.

Zanubrutinib Approved in the U.S. for Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL)

MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting

ASCO 2022: Survival Outcomes in Patients with Chronic Lymphocytic Leukemia Treated at Academic Centers

Some Good News About Costs for Targeted Oral Anti-Cancer Drugs for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

ASCO 2022: Racial and Socioeconomic Disparities among Patients with Chronic Lymphocytic Leukemia: Analysis of Surveillance, Epidemiology, and End Results Program Data

The Inflation Reduction Act: Big Changes to Medicare

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT